PubRank

L Aledort

Author PubWeight™ 29.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993 3.58
2 Are randomized clinical trials the only truth? Not always. J Thromb Haemost 2006 3.34
3 Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975 2.10
4 Haemophilia treatment centres: old and new challenges. Lancet 1995 1.46
5 Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood 1988 1.45
6 Colonoscopic polypectomy in patients with bleeding disorders. Endoscopy 1991 1.38
7 Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol 2001 1.35
8 HTLV-III/LAV antibody and immune status of household contacts and sexual partners of persons with hemophilia. JAMA 1986 1.31
9 Sexual behavior change among human immunodeficiency virus-infected adolescents with hemophilia. Adolescent Hemophilia Behavioral Intervention Evaluation Project Study Group. Pediatrics 2000 1.21
10 Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus infections in relation to human immunodeficiency virus type 1 infection in selected recipient populations. Transfusion Safety Study Group. J Acquir Immune Defic Syndr 1989 1.00
11 Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009 0.93
12 Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990 0.92
13 Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol 1980 0.86
14 Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995 0.81
15 The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011 0.81
16 Tertiary prophylaxis in adults: is there a rationale? Haemophilia 2012 0.80
17 Early platelet activation, inflammation and acute brain injury after a subarachnoid hemorrhage: a pilot study. J Thromb Haemost 2012 0.79
18 The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia 2007 0.79
19 Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia 2008 0.79
20 Factors associated with persistent thrombocytopenia after liver transplantation. Transplant Proc 2010 0.79
21 Treatment of patients with acquired inhibitors. J Thromb Haemost 2005 0.78
22 DDAVP for von Willebrand menorrhagia--severe hyponatraemia, haemolysis, seizure, coma.!! Caution. Haemophilia 2009 0.78
23 Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia 2006 0.78
24 Platelet aggregation in relationship to plasma catecholamines in patients with hypertension. Atherosclerosis 1979 0.78
25 Gastrointestinal bleeding in hemophilia as a complication of the use of over the counter non-steroidal anti-inflammatory drugs. Am J Hematol 1994 0.77
26 Sexual evaluation and treatment of ageing males with haemophilia. Haemophilia 2011 0.75
27 Amino acid metabolism of platelets in leukemia. Cancer Res 1976 0.75
28 Safety of human plasma-derived clotting factor products and their role in haemostasis in patients with haemophilia: meeting report. Haemophilia 2007 0.75
29 Albumin-free formulated recombinant factor VIII preparations--how big a step forward? Thromb Haemost 1999 0.75
30 Functional changes in platelets during extracorporeal circulation. Ann Thorac Surg 1975 0.75
31 Immune status of blood product recipients. JAMA 1985 0.75
32 Assessment for evidence of non A-non B hepatitis in patients given n-heptane-suspended heat-treated clotting factor concentrates. Thromb Res 1987 0.75
33 A study of hepatitis A virus infection among hemophilia patients in New York City. Transfusion 1995 0.75
34 Platelet lipid peroxides as determinant of platelet survival and sympathetic stimulation in patients with hypertension. Biochem Med 1979 0.75
35 Inhibitor challenges in the paediatric setting. Haemophilia 2006 0.75
36 Intracranial meningioma in factor IX deficiency. JAMA 1978 0.75
37 The labeling of dicarboxylic amino acids and their amides by glucose and acetate in human platelets. J Lab Clin Med 1970 0.75
38 Efficacy evaluation of products for treatment of bleeding episodes. Haemophilia 2012 0.75
39 Perfusion without donor blood. J Thorac Cardiovasc Surg 1972 0.75
40 Human platelets: amino acid synthesis. Proc Soc Exp Biol Med 1969 0.75
41 How we treat: venous thromboembolism prevention in haemophilia patients undergoing major orthopaedic surgery. Haemophilia 2009 0.75
42 On the treatment of hemorrhage in patients with hemophilia and associated inhibitors. Transfusion 2001 0.75
43 The platelet in the obliterate vascular rejection phenomenon. Transplant Proc 1973 0.75